Patrick Treanor
Director/Board Member chez KALVISTA PHARMACEUTICALS, INC.
Fortune : - $ au 31/03/2024
Profil
Patrick A.
Treanor is an Independent Director at KalVista Pharmaceuticals, Inc., a Director at XORTX Therapeutics, Inc., and the former President of Vifor Pharma, Inc. He was also the Chief Operating Officer at Pathalys Pharma, Inc. and held Vice President positions at Oscient Pharmaceuticals Corp., Insulet Corp., AMAG Pharmaceuticals, Inc., and Relypsa, Inc. Treanor holds a Master's in Business Administration from Rensselaer Polytechnic Institute and an undergraduate degree from Bryant University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/09/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Patrick Treanor
| Sociétés | Poste | Début |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Director/Board Member | 26/05/2022 |
| XORTX THERAPEUTICS INC. | Director/Board Member | 31/12/2023 |
Pathalys Pharma, Inc.
 Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Chief Operating Officer | 01/07/2021 |
Anciens postes connus de Patrick Treanor
| Sociétés | Poste | Fin |
|---|---|---|
Vifor Pharma, Inc.
 Vifor Pharma, Inc. Medical/Nursing ServicesHealth Services Vifor Pharma, Inc. is an American company that specializes in iron deficiency, nephrology, and cardio-renal therapies. The company is based in Redwood. | President | 01/06/2021 |
| INSULET CORPORATION | Sales & Marketing | 01/04/2015 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/01/2007 |
| AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| RELYPSA INC | Corporate Officer/Principal | - |
Formation de Patrick Treanor
| Rensselaer Polytechnic Institute | Masters Business Admin |
| Bryant University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INSULET CORPORATION | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| XORTX THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Vifor Pharma, Inc.
Vifor Pharma, Inc. Medical/Nursing ServicesHealth Services Vifor Pharma, Inc. is an American company that specializes in iron deficiency, nephrology, and cardio-renal therapies. The company is based in Redwood. | Health Services |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
